Body mass index can determine the healing of reflux esophagitis with Los Angeles grades C and D by esomeprazole

American Journal of Gastroenterology

Volumn 103, Issue 9, 2008, Pages 2209-2214

  Sheu, Bor Shyang ^a,b   Chang, Wei Lun ^a   Cheng, Hsui Chi ^a   Kao, Ai Wen ^a   Lu, Cheng Chan ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; ESOMEPRAZOLE;

ADULT; ARTICLE; BODY MASS; CLINICAL TRIAL; COFFEE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; ESOPHAGOSCOPY; FEMALE; FOLLOW UP; GENOTYPE; HEALING; HIATUS HERNIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; RISK FACTOR;

ANALYSIS OF VARIANCE; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; BODY MASS INDEX; CHI-SQUARE DISTRIBUTION; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGITIS, PEPTIC; ESOPHAGOSCOPY; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 50649085480     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2008.01979.x     Document Type: Article

References (25)

1. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: Clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999 45 : 172 80.
2. Van Soest EM, Siersema PD, Dieleman JP, et al. Persistence and adherence to proton pump inhibitors in daily clinical practice. Aliment Pharmacol Ther 2006 24 : 377 85
3. Lind T, Havelund T, Lundell L, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999 13 : 907 14.
4. Talley NJ, Lauritsen K, Tunturi-Hihnala H, et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: A controlled trial of "on-demand' therapy for 6 months. Aliment Pharmacol Ther 2001 15 : 347 54.
5. Dent J, Brun J, Fendrick A, et al. An evidence-based appraisal of reflux disease management - the Genval workshop report. Gut 1999 44 : S1 16.
6. Chang M, Tybring G, Dahl ML, et al. Interphenotype differences in disposition and effect on gastrin levels of omeprazole: suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995 39 : 511 8.
7. de Morais SM, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994 269 : 15419 22.
8. Hatlebakk JG. Review article: Gastric acidity - comparison of esomeprazole with other proton pump inhibitors. Aliment Pharmacol Ther 2003 17 (Suppl 1 10 7.
9. 2 in exon 4, in Japanese subjects. Clin Pharmacol Ther 1996 59 : 647 53.
10. Thitiphuree S, Talley NJ. Esomeprazole, a new proton pump inhibitor: Pharmacological characteristics and clinical efficacy. Int J Clin Pract 2000 54 : 537 41.
11. Andersson T, Rohss K, Bredberg E, et al. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment Pharmacol Ther 2001 15 : 1563 9.
12. Sheu BS, Kao AW, Cheng HC, et al. Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. Aliment Pharmacol Ther 2005 21 : 283 8.
13. Kawabata H, Habu Y, Tomioka H, et al. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. Aliment Pharmacol Ther 2002 17 : 259 64.
14. Furuta T, Shirai N, Takashima M, et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 2001 68 : 158 68.
15. El-Serag HB, Graham DY, Satia JA, et al. Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am J Gastroenterol 2005 100 : 1243 50.
16. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: Obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005 143 : 199 211.
17. Murray L, Johnston B, Lane A, et al. Relationship between body mass and gastro-oesophageal reflux symptoms: The Bristol Helicobacter Project. Int J Epidemiol 2003 32 : 645 50.
18. Jacobson BC, Somers SC, Fuchs CS, et al. Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med 2006 354 : 2340 8.
19. El-Serag HB, Ergun GA, Pandolfino J, et al. Obesity increases esophageal acid exposure. Gut 2007 56 : 749 55.
20. Sheu BS, Cheng HC, Chang WL, et al. The impact of body mass index on the application of on-demand therapy for Los Angeles grades A and B reflux esophagitis. Am J Gastroenterol 2007 102 : 2387 94.
21. Kahrilas PJ, Dent J, Lauritsen K, et al. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol 2007 5 : 1385 91.
22. Kahrilas PJ, Falk GW, Johnson DA, et al. The Esomeprazole Study Investigators. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: A randomized controlled trial. Aliment Pharmacol Ther 2000 14 : 1249 58.
23. Fennerty MB, Johanson JF, Hwang C, et al. Efficacy of esomeprazole 40 mg versus lansoprazole 30 mg for healing moderate to severe erosive oesophagitis. Aliment Pharmacol Ther 2005 21 : 455 63.
24. Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002 97 : 575 83.
25. Devault KR, Johanson JF, Johnson DA, et al. Maintenance of healed erosive esophagitis: A randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams. Clin Gastroenterol Hepatol 2006 4 : 852 9.